What do international guidelines say about therapy?

Journal of Hypertension, Supplement

Volumn 19, Issue 3, 2001, Pages

  Thakkar, R B ^a   Oparil, S ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

1999 Canadian recommendations for the management of hypertension; And Treatment of High Blood Pressure; Antihypertensive therapy; British Hypertension Society; Detection; Evaluation; Hypertension guidelines; Sixth report of the Joint National Committee on Prevention; World Health Organization International Society of Hypertension

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

CANADA; DRUG INDICATION; HUMAN; HYPERTENSION; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; UNITED KINGDOM; WORLD HEALTH ORGANIZATION; BLOOD PRESSURE; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; EUROPE; FORECASTING; PERCEPTIVE THRESHOLD; PHYSIOLOGY; RISK FACTOR; STANDARD; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CORONARY ARTERIOSCLEROSIS; EUROPE; FORECASTING; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; RISK FACTORS; SENSORY THRESHOLDS; UNITED STATES;

EID: 0035171823     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Critical assessment of hypertension guidelines
2. Guidelines for management of hypertension: Report of the third working party of the British Hypertension Society
3. 1999 Canadian recommendations for the management of hypertension
4. Lifestyle modifications to prevent and control hypertension: 1. Methods and overview of the Canadian recommendations
5. Lifestyle modifications to prevent and control hypertension: 2. Recommendations on obesity and weight loss
6. Lifestyle modifications to prevent and control hypertension: 3. Recommendations on alcohol consumption
7. Lifestyle modifications to prevent and control hypertension: 4. Recommendations on physical exercise training
8. Lifestyle modifications to prevent and control hypertension: 5. Recommendations on dietary salt
9. Lifestyle modifications to prevent and control hypertension: 6. Recommendations on potassium, magnesium and calcium
10. Lifestyle modifications to prevent and control hypertension: 7. Recommendations on stress management
11. The sixth report
12. 1999 World Health Organization-International Society of hypertension guidelines for the management of hypertension
13. Risk stratification in hypertension: New insights from the Framingham study
14. Cross-classification of JNC VI blood pressure stages and risk groups in the Framingham Heart Study
15. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
16. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial
17. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
18. The effects of non-pharmacological interventions on blood pressure of persons with high normal levels: Results of the Trials of Hypertension Prevention (Phase I)
19. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure: The Trials of Hypertension Prevention, Phase II
20. Achievement and safety of a low blood pressure goal in chronic renal disease
21. A clinical trial of the effects of dietary patterns on blood pressure
22. Sodium reduction and weight loss in the treatment of hypertension in older persons. A randomized controlled trial of nonpharmacologic interventions in the elderly (TONE)
23. Effects of moderate sodium restriction on clinic and twenty-four-hour ambulatory blood pressure in elderly hypertensive subjects
24. Interactions between the effects of exercise and weight loss on risk factors, cardiovascular haemodynamics and left ventricular structure in overweight subjects
25. Effect of reduced dietary sodium on blood pressure. A meta-analysis of randomized controlled trials
26. Refractory hypertension
27. Regular alcohol use raises blood pressure in treated hypedensive subjects. A randomized controlled trial
28. Managing the patient with hard-to-control hypertension
29. How much alcohol and how often? Population based case-control study of alcohol consumption and risk of a major coronary event
30. 27th Bethesda conference: Matching the intensity of risk factor management with the hazard for coronary disease events. 1995 Sept 14-15
31. A meta-analysis of alcohol consumption in relation to risk of breast cancer
32. Alcohol consumption - A risk factor for hemorrhagic and non-hemorrhagic stroke
33. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials
34. Hypokalemia
35. New guidelines for potassium replacement in clinical practice. A contemporary review by the National Council on Potassium in Clinical Practice
36. Diet-micronutrients-special foods
37. Essential hypertension Part II: Treatment
38. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP)
39. Medical Research Council trial of treatment of hypertension in older adults: Principal results
40. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
41. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial on Old Patients with Hypertension-2 study
42. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study
43. Influence of diabetes and type of hypertension on response to antihypertensive treatment
44. Preserving renal function in adults with hypertension and diabetes: A consensus approach
45. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
46. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
47. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
48. Pharmacokinetics and pharmacodynamics: Dose selection and the time course of drug action
49. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
50. Diabetes and syndrome X: Focus on reduction of cardiovascular and renal events
51. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy
52. Renal effects of diltiazem in primary hypertension
53. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease
54. Comparative renal hemodynamic effects of lisinopril, verapamil, and amlodipine in patients with chronic renal failure
55. Diltiazem: Ten years of clinical experience in the treatment of hypertension
56. Evaluation of enalapril/diltiazem ER in hypertensive patients with coexisting renal dysfunction
57. Beta blockade during and after myocardial infarction: An overview of the randomized trials
58. Adjunctive drug therapy of acute myocardial infarction-evidence from clinical trials
59. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
60. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
61. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
62. The Cardiac Insufficiency Bisoprolol Study (CIBIS-II): A randomized trial
63. Effect of metoprolol CIR/XL in chronic heart failure: Metoprolol CIR/XL randomized intervention trial in congestive heart failure (MERIT-HF)
64. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
65. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomized trial-the losartan heart failure survival study ELITE II
66. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
67. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
68. Hypertension in women
69. The effect of hormone replacement therapy on blood pressure and cardiovascular risk factors in women with moderate hypertension
70. Experimental approaches to determining the choice of first step therapy for patients with hypertension. The ALLHAT Research Group. Antihypertensive and Lipid Lowering Treatment to prevent heart attack trial
71. On behalf of the ASCOT steering committee
72. Rationale and design for the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial
73. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): An Internet-based randomized trial in coronary artery disease patients with hypertension
74. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design